Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10398184,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) were observed between 0. 33 and 0.75 hr following dolasetron infusion.,Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10398184/),h,0. 33 and 0.75,10083,DB00757,Dolasetron
,10398184,t1/2,"For 1.8-mg/kg dolasetron, the t1/2 was 4.98 hr and the maximum plasma concentration (tmax) 0.47 hr.",Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10398184/),h,4.98,10084,DB00757,Dolasetron
,10398184,maximum plasma concentration (tmax),"For 1.8-mg/kg dolasetron, the t1/2 was 4.98 hr and the maximum plasma concentration (tmax) 0.47 hr.",Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10398184/),h,0.47,10085,DB00757,Dolasetron
less,9475818,elimination half-life (t1/2),"Plasma dolasetron concentrations declined rapidly in all three infusion rate groups, with mean elimination half-life (t1/2) of less than 10 minutes.",Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9475818/),min,10,18600,DB00757,Dolasetron
,9475818,t1/2,"The reduced metabolite hydrodolasetron, which accounts for most pharmacologic activity, formed rapidly, with maximum concentrations occurring between 0.4 and 0.5 hours and disappeared with a mean t1/2 of 8-9 hours.",Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9475818/),h,8-9,18601,DB00757,Dolasetron
,10423655,peak plasma concentrations,"The reduced metabolite, hydrodolasetron, was formed rapidly with peak plasma concentrations (group I, mean = 128.6 ng/mL; group II, mean = 505.3 ng/mL) occurring at or shortly after the end of the infusion.",Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423655/),[ng] / [ml],128.6,27964,DB00757,Dolasetron
,10423655,peak plasma concentrations,"The reduced metabolite, hydrodolasetron, was formed rapidly with peak plasma concentrations (group I, mean = 128.6 ng/mL; group II, mean = 505.3 ng/mL) occurring at or shortly after the end of the infusion.",Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423655/),[ng] / [ml],505.3,27965,DB00757,Dolasetron
,9510981,time to Cmax,"The time to Cmax was statistically significantly longer after the high-fat breakfast (mean values, 1.11 h fasting and 1.80 h fed), probably due to delayed gastric emptying.",The effect of food on the bioavailability of dolasetron mesylate tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510981/),h,1.11,34629,DB00757,Dolasetron
,9510981,time to Cmax,"The time to Cmax was statistically significantly longer after the high-fat breakfast (mean values, 1.11 h fasting and 1.80 h fed), probably due to delayed gastric emptying.",The effect of food on the bioavailability of dolasetron mesylate tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510981/),h,1.80,34630,DB00757,Dolasetron
,8818990,terminal elimination half-life (t1/2),"Pharmacokinetic parameters of dolasetron showed a terminal elimination half-life (t1/2) of 0.1 h, total body plasma clearance (Cltot) of around 109 mL/min/kg, apparent volume of distribution (aVd beta) of 0.83 L/kg, and bioavailability (F) of 7%.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),h,0.1,56224,DB00757,Dolasetron
,8818990,total body plasma clearance (Cltot),"Pharmacokinetic parameters of dolasetron showed a terminal elimination half-life (t1/2) of 0.1 h, total body plasma clearance (Cltot) of around 109 mL/min/kg, apparent volume of distribution (aVd beta) of 0.83 L/kg, and bioavailability (F) of 7%.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),[ml] / [kg·min],109,56225,DB00757,Dolasetron
,8818990,apparent volume of distribution (aVd beta),"Pharmacokinetic parameters of dolasetron showed a terminal elimination half-life (t1/2) of 0.1 h, total body plasma clearance (Cltot) of around 109 mL/min/kg, apparent volume of distribution (aVd beta) of 0.83 L/kg, and bioavailability (F) of 7%.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),[l] / [kg],0.83,56226,DB00757,Dolasetron
,8818990,bioavailability (F),"Pharmacokinetic parameters of dolasetron showed a terminal elimination half-life (t1/2) of 0.1 h, total body plasma clearance (Cltot) of around 109 mL/min/kg, apparent volume of distribution (aVd beta) of 0.83 L/kg, and bioavailability (F) of 7%.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),%,7,56227,DB00757,Dolasetron
,8818990,t1/2,"The t1/2 was around 4.0 h, Cltot 25 mL/min/kg, aVd beta 8.5 L/kg, and F around 100%.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),h,4.0,56228,DB00757,Dolasetron
,8818990,Cltot,"The t1/2 was around 4.0 h, Cltot 25 mL/min/kg, aVd beta 8.5 L/kg, and F around 100%.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),[ml] / [kg·min],25,56229,DB00757,Dolasetron
,8818990,F,"The t1/2 was around 4.0 h, Cltot 25 mL/min/kg, aVd beta 8.5 L/kg, and F around 100%.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),%,100,56230,DB00757,Dolasetron
,8818990,apparent first-order formation rate constant (ki),"The apparent first-order formation rate constant (ki) of red-dolasetron was 7 h-1, which was similar to the first-order elimination rate constant (kel) of dolasetron.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),1/[h],7,56231,DB00757,Dolasetron
,8818990,Tmax,"Cmax of red-dolasetron was similar, after po administration of either compound, but the median Tmax was 0.33 h after dolasetron, compared with 1.5 h after red-dolasetron.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),h,0.33,56232,DB00757,Dolasetron
,8818990,Tmax,"Cmax of red-dolasetron was similar, after po administration of either compound, but the median Tmax was 0.33 h after dolasetron, compared with 1.5 h after red-dolasetron.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),h,1.5,56233,DB00757,Dolasetron
,8818990,first-order absorption rate constants (ka),"The first-order absorption rate constants (ka) of dolasetron and red-dolasetron were 14 h-1 and 2 h-1, respectively.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),1/[h],14,56234,DB00757,Dolasetron
,8818990,first-order absorption rate constants (ka),"The first-order absorption rate constants (ka) of dolasetron and red-dolasetron were 14 h-1 and 2 h-1, respectively.","Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818990/),1/[h],2,56235,DB00757,Dolasetron
,7787130,half-life,The half-life of reduced metabolite ranged from 3.82 to 7.46 h.,Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787130/),h,3.82 to 7.46,59114,DB00757,Dolasetron
,7787130,renal clearance,The mean renal clearance of reduced metabolite was 2.20-4.43 mL min-1 kg-1 and was dose independent.,Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787130/),[ml] / [kg·min],2.20-4.43,59115,DB00757,Dolasetron
,1467456,terminal disposition half-life,"Its median terminal disposition half-life was 7.56 h; median values for fraction of dose excreted in urine and renal clearance were 31.0 per cent and 2.68 ml min-1 kg-1, respectively.",Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467456/),h,7.56,87143,DB00757,Dolasetron
,1467456,fraction of dose excreted in urine,"Its median terminal disposition half-life was 7.56 h; median values for fraction of dose excreted in urine and renal clearance were 31.0 per cent and 2.68 ml min-1 kg-1, respectively.",Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467456/),%,31.0,87144,DB00757,Dolasetron
,1467456,fraction of dose excreted in urine,"Its median terminal disposition half-life was 7.56 h; median values for fraction of dose excreted in urine and renal clearance were 31.0 per cent and 2.68 ml min-1 kg-1, respectively.",Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467456/),[ml] / [kg·min],2.68,87145,DB00757,Dolasetron
,1467456,renal clearance,"Its median terminal disposition half-life was 7.56 h; median values for fraction of dose excreted in urine and renal clearance were 31.0 per cent and 2.68 ml min-1 kg-1, respectively.",Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467456/),[ml] / [kg·min],2.68,87146,DB00757,Dolasetron
less,10086835,elimination half-life (t1/2),"Following intravenous administration, dolasetron was rapidly eliminated from plasma, with a mean elimination half-life (t1/2) of less than 10 min.",Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086835/),min,10,112684,DB00757,Dolasetron
less,10086835,time to maximum concentration (t(max)),"Hydrodolasetron, the active primary metabolite of dolasetron, appeared rapidly in plasma following both oral and intravenous administration of dolasetron mesylate, with a mean time to maximum concentration (t(max)) of less than 1 h.",Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086835/),h,1,112685,DB00757,Dolasetron
,10086835,t1/2,The mean t1/2 of hydrodolasetron ranged from 6.6-8.8 h.,Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086835/),h,6.6-8.8,112686,DB00757,Dolasetron
,10086835,'apparent' bioavailability,The mean 'apparent' bioavailability of dolasetron calculated using plasma concentrations of hydrodolasetron was 76%.,Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086835/),%,76,112687,DB00757,Dolasetron
,9158883,t1/2,Dolasetron was widely distributed and rapidly reduced (mean t1/2 = 0.23 h) to MDL 74156 (mean t1/2 = 8.05 and 9.12 h after intravenous and oral administration respectively).,Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158883/),h,0.23,116582,DB00757,Dolasetron
,9158883,t1/2,Dolasetron was widely distributed and rapidly reduced (mean t1/2 = 0.23 h) to MDL 74156 (mean t1/2 = 8.05 and 9.12 h after intravenous and oral administration respectively).,Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158883/),h,8.05,116583,DB00757,Dolasetron
,9158883,t1/2,Dolasetron was widely distributed and rapidly reduced (mean t1/2 = 0.23 h) to MDL 74156 (mean t1/2 = 8.05 and 9.12 h after intravenous and oral administration respectively).,Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158883/),h,9.12,116584,DB00757,Dolasetron
,9058532,plasma clearance,"Good predictions of human pharmacokinetic parameters of RD were obtained for plasma clearance (1.7 l/min predicted versus 1.61/min observed), half-life (6.0 h predicted versus 5.6 h observed), and volume of distribution (860.91 predicted versus 770.41 observed).",Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058532/),[l] / [min],1.7,127280,DB00757,Dolasetron
,9058532,plasma clearance,"Good predictions of human pharmacokinetic parameters of RD were obtained for plasma clearance (1.7 l/min predicted versus 1.61/min observed), half-life (6.0 h predicted versus 5.6 h observed), and volume of distribution (860.91 predicted versus 770.41 observed).",Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058532/),1/[min],1.61,127281,DB00757,Dolasetron
,9058532,half-life,"Good predictions of human pharmacokinetic parameters of RD were obtained for plasma clearance (1.7 l/min predicted versus 1.61/min observed), half-life (6.0 h predicted versus 5.6 h observed), and volume of distribution (860.91 predicted versus 770.41 observed).",Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058532/),h,6.0,127282,DB00757,Dolasetron
,9058532,half-life,"Good predictions of human pharmacokinetic parameters of RD were obtained for plasma clearance (1.7 l/min predicted versus 1.61/min observed), half-life (6.0 h predicted versus 5.6 h observed), and volume of distribution (860.91 predicted versus 770.41 observed).",Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058532/),h,5.6,127283,DB00757,Dolasetron
,9058532,volume of distribution,"Good predictions of human pharmacokinetic parameters of RD were obtained for plasma clearance (1.7 l/min predicted versus 1.61/min observed), half-life (6.0 h predicted versus 5.6 h observed), and volume of distribution (860.91 predicted versus 770.41 observed).",Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058532/),,860.91,127284,DB00757,Dolasetron
,9058532,volume of distribution,"Good predictions of human pharmacokinetic parameters of RD were obtained for plasma clearance (1.7 l/min predicted versus 1.61/min observed), half-life (6.0 h predicted versus 5.6 h observed), and volume of distribution (860.91 predicted versus 770.41 observed).",Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058532/),,770.41,127285,DB00757,Dolasetron
,9505984,t1/2,The mean t1/2 increased from 6.87 hours in group I to 11.69 hours in group III.,Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505984/),h,6.87,130966,DB00757,Dolasetron
,9505984,t1/2,The mean t1/2 increased from 6.87 hours in group I to 11.69 hours in group III.,Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505984/),h,11.69,130967,DB00757,Dolasetron
,15139789,terminal elimination half-life,"Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate (62%) plasma protein binding.",Palonosetron. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139789/),h,40,174042,DB00757,Dolasetron
,15899109,plasma elimination half-life,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),h,40,174671,DB00757,Dolasetron
,15899109,plasma elimination half-life,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),h,43,174672,DB00757,Dolasetron
,15899109,total body clearance,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),[ml] / [min],130,174673,DB00757,Dolasetron
,15899109,total body clearance,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),[ml] / [min],136,174674,DB00757,Dolasetron
,15899109,volume of distribution at steady-state,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),l,410.9,174675,DB00757,Dolasetron
,15899109,volume of distribution at steady-state,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),l,442.3,174676,DB00757,Dolasetron
,10445889,half-life (t1/2),"The half-life (t1/2) in plasma was approximately 6 hours for all dose levels, and the mean clearance (CLapp) was unrelated to dose.","Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445889/),h,6,188986,DB00757,Dolasetron
,28905667,maximum serum concentration (Cmax),"Median (range) PK parameters for IV hydrodolasetron were as follows: maximum serum concentration (Cmax) 116 ng/ml (69-316 ng/ml), time to maximum concentration (Tmax) 0.5 h (0.3-0.5 h), half-life 3.3 h (2.9-7.2 h) and area under the curve until the last measurable concentration (AUClast) 323 h/ng/ml (138-454 h/ng/ml).",Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905667/),[ng] / [ml],116,201746,DB00757,Dolasetron
,28905667,time to maximum concentration (Tmax),"Median (range) PK parameters for IV hydrodolasetron were as follows: maximum serum concentration (Cmax) 116 ng/ml (69-316 ng/ml), time to maximum concentration (Tmax) 0.5 h (0.3-0.5 h), half-life 3.3 h (2.9-7.2 h) and area under the curve until the last measurable concentration (AUClast) 323 h/ng/ml (138-454 h/ng/ml).",Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905667/),h,0.5,201747,DB00757,Dolasetron
,28905667,half-life,"Median (range) PK parameters for IV hydrodolasetron were as follows: maximum serum concentration (Cmax) 116 ng/ml (69-316 ng/ml), time to maximum concentration (Tmax) 0.5 h (0.3-0.5 h), half-life 3.3 h (2.9-7.2 h) and area under the curve until the last measurable concentration (AUClast) 323 h/ng/ml (138-454 h/ng/ml).",Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905667/),h,3.3,201748,DB00757,Dolasetron
,28905667,area under the curve until the last measurable concentration (AUClast),"Median (range) PK parameters for IV hydrodolasetron were as follows: maximum serum concentration (Cmax) 116 ng/ml (69-316 ng/ml), time to maximum concentration (Tmax) 0.5 h (0.3-0.5 h), half-life 3.3 h (2.9-7.2 h) and area under the curve until the last measurable concentration (AUClast) 323 h/ng/ml (138-454 h/ng/ml).",Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905667/),[h] / [ml·ng],323,201749,DB00757,Dolasetron
,28905667,Cmax,"Median (range) PK parameters for SC hydrodolasetron were as follows: Cmax 67.9 ng/ml (60.4-117 ng/ml), Tmax 0.5 h (0.5-1.0 h), half-life 3.8 h (2.9-5.3 h) and AUClast 437 h/ng/ml (221.5-621.8 h/ng/ml).",Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905667/),[ng] / [ml],67.9,201750,DB00757,Dolasetron
,28905667,Tmax,"Median (range) PK parameters for SC hydrodolasetron were as follows: Cmax 67.9 ng/ml (60.4-117 ng/ml), Tmax 0.5 h (0.5-1.0 h), half-life 3.8 h (2.9-5.3 h) and AUClast 437 h/ng/ml (221.5-621.8 h/ng/ml).",Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905667/),h,0.5,201751,DB00757,Dolasetron
,28905667,half-life,"Median (range) PK parameters for SC hydrodolasetron were as follows: Cmax 67.9 ng/ml (60.4-117 ng/ml), Tmax 0.5 h (0.5-1.0 h), half-life 3.8 h (2.9-5.3 h) and AUClast 437 h/ng/ml (221.5-621.8 h/ng/ml).",Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905667/),h,3.8,201752,DB00757,Dolasetron
,28905667,AUClast,"Median (range) PK parameters for SC hydrodolasetron were as follows: Cmax 67.9 ng/ml (60.4-117 ng/ml), Tmax 0.5 h (0.5-1.0 h), half-life 3.8 h (2.9-5.3 h) and AUClast 437 h/ng/ml (221.5-621.8 h/ng/ml).",Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905667/),[h] / [ml·ng],437,201753,DB00757,Dolasetron
,8453023,terminal disposition half-life,The median terminal disposition half-life was 7.80 h.,Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453023/),h,7.80,214581,DB00757,Dolasetron
,8453023,fraction of dose excreted in urine,Median values for fraction of dose excreted in urine and renal clearance were 22.2 per cent and 2.56 ml min-1 kg-1.,Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453023/),%,22.2,214582,DB00757,Dolasetron
,8453023,renal clearance,Median values for fraction of dose excreted in urine and renal clearance were 22.2 per cent and 2.56 ml min-1 kg-1.,Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453023/),[ml] / [kg·min],2.56,214583,DB00757,Dolasetron
,9923817,tmax,"Small differences were found in mean tmax (0.7 to 0.8 h), CLr (2.0 to 2.6 ml/min per kg), and t1/2 (7.4 to 8.8 h) for hydrodolasetron between treatment periods.",Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923817/),h,0.7 to 0.8,231686,DB00757,Dolasetron
,9923817,CLr,"Small differences were found in mean tmax (0.7 to 0.8 h), CLr (2.0 to 2.6 ml/min per kg), and t1/2 (7.4 to 8.8 h) for hydrodolasetron between treatment periods.",Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923817/),[ml] / [kg·min],2.0 to 2.6,231687,DB00757,Dolasetron
,9923817,t1/2,"Small differences were found in mean tmax (0.7 to 0.8 h), CLr (2.0 to 2.6 ml/min per kg), and t1/2 (7.4 to 8.8 h) for hydrodolasetron between treatment periods.",Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923817/),h,7.4 to 8.8,231688,DB00757,Dolasetron
,8930777,half-life (t1/2),The mean half-life (t1/2) of dolasetron was 0.24 hours after intravenous administration and 0.50 hours after oral administration.,Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930777/),h,0.24,233605,DB00757,Dolasetron
,8930777,half-life (t1/2),The mean half-life (t1/2) of dolasetron was 0.24 hours after intravenous administration and 0.50 hours after oral administration.,Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930777/),h,0.50,233606,DB00757,Dolasetron
,8930777,apparent absolute bioavailability,"The apparent absolute bioavailability of the reduced metabolite was 89%, and it had an elimination t1/2 of approximately 7 hours and an apparent volume of distribution (Vd beta) of 4.69 L/kg.",Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930777/),%,89,233607,DB00757,Dolasetron
,8930777,elimination t1/2,"The apparent absolute bioavailability of the reduced metabolite was 89%, and it had an elimination t1/2 of approximately 7 hours and an apparent volume of distribution (Vd beta) of 4.69 L/kg.",Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930777/),h,7,233608,DB00757,Dolasetron
,8930777,apparent volume of distribution (Vd beta),"The apparent absolute bioavailability of the reduced metabolite was 89%, and it had an elimination t1/2 of approximately 7 hours and an apparent volume of distribution (Vd beta) of 4.69 L/kg.",Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930777/),[l] / [kg],4.69,233609,DB00757,Dolasetron
,11862273,apparent oral clearance,The mean apparent oral clearance ranged from 9.89 to 23.10 ml min(minus sign1) kg(minus sign1).,"Single- and Multiple-Dose Pharmacokinetics of Reduced Metabolite (MDL 74,156) following Oral Administration of Dolasetron Mesylate to Normal Male Subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862273/),min·ml,9.89 to 23.10,254941,DB00757,Dolasetron
,11862273,half-life,The half-life ranged from 5.20 to 10.80 h.,"Single- and Multiple-Dose Pharmacokinetics of Reduced Metabolite (MDL 74,156) following Oral Administration of Dolasetron Mesylate to Normal Male Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862273/),h,5.20 to 10.80,254942,DB00757,Dolasetron
,11862273,renal clearance,"Mean renal clearance and fraction of dose excreted in urine were 0.97 to 3.97 ml min(minus sign1) kg(minus sign1) and 7.47 to 31.9%, respectively.","Single- and Multiple-Dose Pharmacokinetics of Reduced Metabolite (MDL 74,156) following Oral Administration of Dolasetron Mesylate to Normal Male Subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862273/),min·ml,0.97 to 3.97,254943,DB00757,Dolasetron
,11862273,fraction of dose excreted in urine,"Mean renal clearance and fraction of dose excreted in urine were 0.97 to 3.97 ml min(minus sign1) kg(minus sign1) and 7.47 to 31.9%, respectively.","Single- and Multiple-Dose Pharmacokinetics of Reduced Metabolite (MDL 74,156) following Oral Administration of Dolasetron Mesylate to Normal Male Subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862273/),%,7,254944,DB00757,Dolasetron
more,22645289,extraction recoveries,"The extraction recoveries obtained from the SIPSE method were all more than 96% for dolasetron, hydrodolasetron and ondansetron (internal standard).",Optimization of sample pretreatment methods for simultaneous determination of dolasetron and hydrodolasetron in human plasma by HPLC-ESI-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22645289/),%,96,266619,DB00757,Dolasetron
less,10086836,time to maximum concentration (t(max)),"Hydrodolasetron was formed rapidly, with a time to maximum concentration (t(max)) of less than 1 h.",Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086836/),h,1,267118,DB00757,Dolasetron
